- Home
- LOPE vs PTGX Comparison
LOPE vs PTGX Comparison
Compare LOPE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOPE | PTGX |
|---|---|---|
| Founded | 1949 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.2B |
| IPO Year | 2008 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LOPE | PTGX |
|---|---|---|
| Price | $163.54 | $96.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $220.00 | $100.17 |
| AVG Volume (30 Days) | 283.0K | ★ 567.4K |
| Earning Date | 05-21-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.71 | N/A |
| Revenue | ★ $511,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.99 | N/A |
| P/E Ratio | $21.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $149.37 | $39.60 |
| 52 Week High | $223.04 | $100.00 |
Technical Indicators
Market Signals| Indicator | LOPE | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 62.40 |
| Support Level | $151.84 | $76.63 |
| Resistance Level | $168.28 | $100.00 |
| Average True Range (ATR) | 4.64 | 4.18 |
| MACD | 0.63 | 0.34 |
| Stochastic Oscillator | 67.36 | 74.27 |
Price Performance
Historical ComparisonAbout LOPE Grand Canyon Education Inc.
Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges both online, on the ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.